SEC Form 10-Q Summary
Filing identity: The provided filing is for NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), not Metavia Inc. It covers the quarter and nine months ended September 30, 2020, and was signed November 13, 2020. The financial statements are unaudited.
Business Context and Reporting Period
NeuroBo is a clinical-stage biotechnology company developing NB-01 for neuropathic pain, NB-02 for neurodegenerative diseases, and Gemcabene for dyslipidemia and liver-related indications. The company has no product revenue and has funded operations primarily through equity and debt financing.
The December 30, 2019 merger with Private NeuroBo was accounted for as a reverse asset acquisition. Prior-period operating results principally reflect Private NeuroBo.
Financial Performance and Position
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.3 million vs. $1.2 million | $4.1 million vs. $3.9 million |
| General and administrative expense | $1.8 million vs. $2.5 million | $6.1 million vs. $4.1 million |
| Total operating expenses | $3.1 million vs. $3.6 million | $10.2 million vs. $8.0 million |
| Net loss | $3.1 million vs. $3.6 million | $10.2 million vs. $8.0 million |
| Loss per share | $0.19 vs. $0.70 | $0.63 vs. $1.55 |
| Net cash used in operating activities | Not separately provided | $8.4 million vs. $5.8 million |
As of September 30, 2020, cash was $12.4 million, total assets were $13.2 million, total liabilities were $3.7 million, and stockholders’ equity was $9.5 million. Accumulated deficit was $47.0 million. The company had no debt outstanding after convertible notes were converted into common stock in connection with the merger.
Cash and restricted cash declined by $1.6 million during the first nine months of 2020. Financing activities provided $6.9 million, primarily from the April 2020 registered direct offering, while investing activities used $2,000.
Material Changes Versus the Prior Comparable Period
- Third-quarter net loss improved by $0.6 million, despite a $0.1 million increase in research and development expense, primarily because prior-year general and administrative expenses included higher merger-related and transaction costs.
- Nine-month net loss increased by $2.2 million. General and administrative expense increased by $2.0 million due largely to public-company costs, director and officer insurance, board costs, stock-based compensation, legal expenses, and facility costs.
- Research and development expense increased by $0.2 million for the nine-month period, reflecting approximately $1.3 million of NB-01 CRO termination costs and $0.8 million of Gemcabene development spending, partly offset by lower clinical activity.
- In April 2020, the company issued 750,000 common shares at $10 per share for gross proceeds of $7.5 million and net financing proceeds of approximately $6.8 million. Placement agent warrants for 37,500 shares were issued at an exercise price of $12.50 per share.
- Outstanding common shares increased to 16.4 million at September 30, 2020 from 15.6 million at December 31, 2019.
Guidance, Outlook, Risks, and Unusual Items
- Management expects existing cash to fund operations into the third quarter of 2021 only at the reduced level of scientific activity described in the filing. Additional financing is required, and no financing commitments were in place.
- The company disclosed substantial doubt about its ability to continue as a going concern. It expects continued losses and negative operating cash flow and may need to reduce, delay, or cease operations if financing is unavailable.
- NB-01 Phase 3 activity was halted in the first quarter of 2020, and related CRO and vendor contracts were terminated. The company is evaluating orphan-drug and nutraceutical alternatives.
- NB-02 IND preparation and initial human trials were postponed to preserve capital, with potential clinical activity targeted for the second half of 2021 if health and macroeconomic conditions improve. A strategic partnership is also being considered.
- Gemcabene’s clinical development program remained subject to an FDA partial clinical hold as of May 2020.
- COVID-19 may affect clinical trials, patient enrollment, suppliers, contract research organizations, manufacturing, capital markets, and future liquidity. The company had not experienced a significant adverse effect on reported operations or cash flows other than adjustments to scientific activity as of the filing.
- The company incurred approximately $1.3 million of NB-01 termination expenses and settled a CRO dispute for $0.7 million during the third quarter.
- Future obligations include potential Gemcabene milestones under the Pfizer license of up to $37 million, although no milestones were triggered through September 30, 2020. The Gemcabene license may also be terminated if first commercial sale does not occur by April 16, 2024.
- Disclosure controls were not effective because of an unremediated material weakness involving accounting for clinical trial costs and related supply materials. Management identified misstatements in clinical prepaids and expenses and was implementing remediation measures.
Investor Verification Checklist
- Confirm that the intended issuer is NeuroBo Pharmaceuticals, Inc., rather than Metavia Inc.
- Assess the company’s ability to obtain additional equity, debt, licensing, or collaboration financing before cash is projected to be exhausted.
- Review the status and feasibility of NB-01’s alternative development paths, NB-02’s expected 2021 clinical timeline, and Gemcabene’s FDA partial clinical hold.
- Evaluate the going-concern disclosure and the effect of continued operating losses and negative cash flow.
- Review the material weakness remediation and any subsequent corrections to clinical trial accounting.
- Consider dilution from future equity offerings, outstanding options, and 78,055 warrants.
- Review COVID-19 effects on clinical execution, supply chains, financing access, and development schedules.